News & Updates

Show Multimedia Only
TYK2 inhibitor for psoriatic arthritis clears phase II trial

TYK2 inhibitor for psoriatic arthritis clears phase II trial

26 Mar 2022

In the treatment of patients with psoriatic arthritis, the use of the selective TYK2 inhibitor deucravacitinib appears to be effective and well tolerated, leading to greater improvements in American College of Rheumatology (ACR) domains, enthesitis endpoints, and multiple patient-reported, psoriasis-related outcomes relative to placebo, as shown in the results of a phase II trial.

TYK2 inhibitor for psoriatic arthritis clears phase II trial

26 Mar 2022
Colchicine touted for prevention of gout flare-ups after COVID-19 vaccination

Colchicine touted for prevention of gout flare-ups after COVID-19 vaccination

18 Mar 2022 byJairia Dela Cruz

Gout patients have about sixfold greater odds of experiencing a flare in the first few months after COVID-19 vaccination, but colchicine appears to keep these gout attacks at bay, as shown in a study from China.

Colchicine touted for prevention of gout flare-ups after COVID-19 vaccination

18 Mar 2022
Schizophrenia genetics not linked to neuropsychiatric features in childhood-onset SLE

Schizophrenia genetics not linked to neuropsychiatric features in childhood-onset SLE

28 Feb 2022
Sarcoidosis patients at risk of haematologic, nonmelanoma skin cancers

Sarcoidosis patients at risk of haematologic, nonmelanoma skin cancers

25 Feb 2022

Sarcoidosis patients with biopsy-verified non-necrotizing granulomatous inflammation are at greater risk of haematologic cancers and nonmelanoma skin cancer (NMSC) in the long term than the general population, a study has found.

Sarcoidosis patients at risk of haematologic, nonmelanoma skin cancers

25 Feb 2022